Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.
Open Access
- 1 September 1985
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 72 (3), 536-546
- https://doi.org/10.1161/01.cir.72.3.536
Abstract
It has been suspected that the increased sympathetic activity seen in patients with chronic congestive heart failure from dilated cardiomyopathy may be harmful. We therefore tested the long-term effect of metoprolol on eight patients in a double-blind, randomized protocol and 12 patients in an unblinded, crossover protocol who were treated for 12 months (range 10 to 24), and compared them with 16 similar subjects who were treated with placebo for 10 months (range 6 to 12) in a double-blind, randomized protocol. Patients were followed by serial clinical assessment, treadmill testing, radionuclide ventriculography, and echocardiography. Metoprolol-treated patients had an improvement in mean exercise capacity by 3 mets (p less than .0001) while experiencing a significant improvement in functional classification (p less than .001) during both the double-blind and open-label crossover studies and had an improved ejection fraction during the double-blind study (p less than .02). These improvements were not seen in matched control subjects receiving placebo. Seven of 20 patients receiving long-term metoprolol therapy had resolution of nearly all symptoms of heart failure, doubled their exercise capacity, and had progressive improvement in resting radionuclide left ventricular ejection fraction (12.6 +/- 3% to 26.9 +/- 6%) and echocardiographic left ventricular end-diastolic dimension (7.7 +/- 0.5 to 6.5 +/- 0.5 cm). Only one of 21 patients treated was intolerant of metoprolol. We conclude that metoprolol can be given safely to a select group of patients with dilated cardiomyopathy in doses that substantially reduce both resting and exercise heart rates. Long-term beta-blockade improved functional class and exercise capacity in 14 of 20 patients while producing an exceptional clinical response in seven that was accompanied by improved resting parameters of left ventricular function.This publication has 22 references indexed in Scilit:
- A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 1985
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureNew England Journal of Medicine, 1984
- Evaluation of metoprolol in suppressing complex ventricular arrhythmiasThe American Journal of Cardiology, 1983
- Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation thresholdThe American Journal of Cardiology, 1983
- Low-dose beta blockade in the treatment of chronic cardiac failureAmerican Heart Journal, 1982
- Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human HeartsNew England Journal of Medicine, 1982
- Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: Relation to pathogenesis of catecholamine cardiomyopathyAmerican Heart Journal, 1981
- Plasma norepinephrine in congestive heart failureThe American Journal of Cardiology, 1978
- Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular diseaseAmerican Heart Journal, 1973
- Treadmill exercise in assessment of the functional capacity of patients with cardiac diseaseThe American Journal of Cardiology, 1972